Showing 4441-4450 of 8203 results for "".
- Lack of Options for Darker Skin Types Hinder Use of Tinted Sunscreenshttps://practicaldermatology.com/news/tinted-sunscreens-lack-options-for-darker-skin-hindering-use/2461156/The lack of tinted sunscreen options for darker skin tones may discourage many people from using these products. This is the main message from a new analysis of consumer preferences of over-the-counter tinted sunscreen products. Sixty-two percent of tinted sunscreen products are only av
- Lilly's Lebrikizumab Combined with Topical Corticosteroids Produces Significant Improvements in AD Disease Severityhttps://practicaldermatology.com/news/lillys-lebrikizumab-combined-with-topical-corticosteroids-produces-significant-improvements-in-ad-disease-severity/2461154/Atopic dermatitis patients taking lebrikizumab plus topical steroids showed significant improvements in disease severity, according to study results from the ADhere trial presented at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference. At 16 weeks, 70 percent of
- Scientists Discover Gene Mutation That Signals Aggressive Melanomahttps://practicaldermatology.com/news/scientists-discover-gene-mutation-that-signals-aggressive-melanoma/2461149/Patients whose melanoma tumors have an ARID2 mutation may have a more aggressive cancer and may need to be treated differently, according to a study published in Cell Reports. &l
- Dermatological Society of New Jersey Kicks Off Virtual Conference Saturdayhttps://practicaldermatology.com/news/dermatological-society-of-new-jersey-kicks-off-virtual-conference-saturday/2461147/The DSNJ annual educational conference is a hybrid event this year, with in person as well as online conference experiences open to attendees across the US. The conference is Saturday, April 9. Penn Medicine Princeton Health, accredited by the Medical Society of New Jersey, designa
- Third Annual San Diego Dermatology Symposium (SDDS) Takes Place in Personhttps://practicaldermatology.com/news/third-annual-san-diego-dermatology-symposium-sdds-takes-place-in-person/2461146/By Caroline Tan, MD, UCLA Dermatology Resident, PGY3 Held for the first time in-person at the Hilton San Diego Bayfront, the Third Annual San Diego Dermatology Symposium (SDDS, March 11-13,
- Practical Dermatology® Names New Interim Digital Practice Editorhttps://practicaldermatology.com/news/practical-dermatology-names-new-interim-digital-practice-editor/2461145/Practical Dermatology® magazine is proud to announce that Vishal Anil Patel, MD will serve as interim editor of our Digital Practice column. Dr. Patel is director of cutaneous oncology at GW Cancer Center, director of dermatologic surgery at GW department of der
- Dermavant's Tapinarof Shows Durable Improvement in PsO in Long-term Extension Studyhttps://practicaldermatology.com/news/dermavants-tapinarof-shows-durable-improvement-in-pso-in-long-term-extension-study/2461140/Results from the Phase 3 PSOARING 3 long-term extension study demonstrate durable improvements across efficacy outcomes, quality of life measures, and tolerability scores with investigational tapinarof cream 1% once daily (QD) for the treatment of plaque psoriasis in adults. The data, f
- Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/long-term-complete-skin-clearance-data-for-bimekizumab-in-moderate-to-severe-plaque-psoriasis/2461137/UCB presented 11 abstracts on bimekizumab in the treatment of adults with moderate to severe plaque psoriasis at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Boston, MA, including a late breaking oral platform presentation and 10 posters. The platform presentation details new
- Dupixent Performs Well in Phase 3s for Prurigo Nodularishttps://practicaldermatology.com/news/dupixent-performs-well-in-phase-3s-for-prurigo-nodularis/2461138/Detailed positive results from the Phase 3 PRIME2 trial show Dupixent® (dupilumab) significantly reduced itch and skin lesions compared to placebo in adults with uncontrolled prurigo nodularis. Findings were presented in a late-breaking session at the American Academy of Dermat
- Phase 3 Data: Sun Pharma’s Winlevi Is Safe and Effective Acne Txhttps://practicaldermatology.com/news/phase-3-data-sun-pharmas-winlevi-is-safe-and-effective-acne-tx/2461134/Results from two Phase 3 pivotal clinical trials showed favorable safety and efficacy data for Winlevi (clascoterone) cream 1% in patients with acne aged 12 years and older. The findings were presented at the American Academy of Dermatol